Abstract
Purpose
It is still relatively questioned if the benefit of Recurrent Score (RS) extends to
invasive lobular carcinoma (ILC), which represents 10-15% of all invasive Breast Cancer
(BC). We present the results of the lobular carcinoma subgroup of the PONDx Italy
study[1]. that collected data on real-life use of the Oncotype DX® test in Italian
oncological community clinical practice.
Methods
We present the results of the lobular carcinoma subgroup of the PONDx Italy study
that collected data on real-life use of the Oncotype DX® test in Italian oncological
community clinical practice. The study primarily evaluated the impact of the Oncotype
DX assay results on physicians' treatment decisions. In the primary analysis, data
from 1724 BC patients who underwent Oncotype DX testing were available from 27 reference
centers located in 6 regions of Italy (Lombardia, Lazio, Emilia Romagna, Campania,
Abruzzo, and Marche).
Results
Among patients with data available, 214 had ILC. In this cohort, 100 (47%) of patients
with ILC had treatment recommendations for CT + HT before the availability of their
RS result. After the availability of the RS result, recommendations for CT+HT decreased
to 47 cases (22%).
Conclusion
the decision to opt for the Oncotype Dx test should not be based on the histology
subgroup only because a small population of ER+ ILC BC patients may still attain important
information from testing. Despite this information, its predictive value needs more
dedicated trials to be confirmed
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.Eur J Cancer. 2016; 66: 104-113
- PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.NPJ Breast Cancer. 2021; 7: 47
- An analysis of oncotype DX recurrence scores and clinico-pathologic characteristics in invasive lobular breast cancer.Breast J. 2017; 23: 677-686
- Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: a National Cancer Database analysis.Cancer. 2022; 128: 1738-1747
- Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.Breast Cancer Res Treat. 2017; 165: 757-763
- 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer.Biomark Med. 2019; 13: 83-93
- International breast cancer study group. distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials.J Clin Oncol. 2008; 26: 3006-3014
- Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis.Cancer Treat Rev. 2021; 97102205
- The impact of chemotherapy prescription on long-term survival outcomes in early-stage invasive lobular carcinoma - a systematic review and meta-analysis.Clin Breast Cancer. 2022; ([published online ahead of print, 2022 Sep 20]) (S1526-8209 00219-1)
Article info
Publication history
Published online: December 13, 2022
Accepted:
December 12,
2022
Received in revised form:
November 2,
2022
Received:
September 15,
2022
Publication stage
In Press Journal Pre-ProofFootnotes
Oncotype Dx test in breast lobular carcinoma
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
